A Prospective Study of Aspirin Use and Primary Prevention of Cardiovascular Disease in Women

JAMA: The Journal of the American Medical Association

Volumn 266, Issue 4, 1991, Pages 521-527

  Manson, JoAnn E ^a,b   Stampfer, Meir J ^a,c   Colditz, Graham A ^a   Willett, Walter C ^a,c   Rosner, Bernard ^a,b   Speizer, Frank E ^a   Hennekens, Charles H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STROKE;

ADULT; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMAN; MIDDLE AGE; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025766535     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1991.03470040085027     Document Type: Article

References (32)

1. Anti-Platelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged anti-platelet therapy. BMJ. 1988;296:320-331.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2:349-360.
3. The Steering Committee of the Physicians’ Health Study Research Group. Final report from the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321:129-135.
4. Peto R, Gray R, Collins R, et al. A randomized trial of the effects of prophylactic daily aspirin among male British doctors. BMJ. 1988;296:320-331.
5. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-756.
6. US Preventive Services Task Force. Aspirin prophylaxis. In: Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. Baltimore, Md: Williams & Wilkins; 1989.
7. Hammond EC, Garfinkel L. Aspirin and coronary heart disease: findings of a prospective study. BMJ. 1975;2:269-271.
8. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort of the elderly. BMJ. 1989;299:1247-1250.
9. Spranger M, Aspey BS, Harrison MJG. Sex difference in antithrombotic effect of aspirin. Stroke. 1989;20:34-37.
10. Escolar G, Bastida E, Garrido M, Rodriguez-Gomez J, Castillo R, Ordinas A. Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium. Thromb Res. 1986;44:837-847.
11. Kelton JG, Hirsch J, Carter CJ, Buchanan MR. Sex differences in the antithrombotic effects of aspirin. Blood. 1978;52:1073-1076.
12. Philpot VB, Lippton HC, Kadowitz PJ. Effect of aspirin on serum thrombin time and bleeding time. Prostaglandins Leukot Med. 1985;19:123-130.
13. Husted SE, Pedersen AK, Petersen T, Geday E. Systemic availability of acetylsalicylic acid in normal men and women and its effect on in vitro platelet aggregability. Eur J Clin Pharmacol. 1983;24:679-682.
14. Ho PC, Triggs EJ, Bourne DWA, Heazlewood VJ. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol. 1985;19:675-684.
15. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
16. Mortality, part B. In: Vital Statistics of the United States, 1986. Washington, DC: US Dept of Health and Human Services; 1988;2:170-195. Publication PHS 88-1114.
17. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044-1049.
18. Rose GA, Blackburn H. Cardiovascular Survey Methods. 2nd ed. Geneva, Switzerland: World Health Organization; 1982. WHO Monograph Series No. 56.
19. Walker AE, Robins M, Weinfield FD. The National Survey of Stroke: clinical findings. Stroke. 1981;12(suppl I):I-13-I-44.
20. Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol. 1984;119:837-839.
21. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976;103:226-235.
22. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, Calif: Lifetime Learning Publishers; 1982.
23. O’Brien JR. Effects of salicylates on human platelets. Lancet. 1968;1:779-783.
24. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med. 1979;300:1142-1147.
25. Patrono C, Ciabattoni G, Patrignani P, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;72:1177-1184.
26. Patrono C, Ciabattoni G, Pinca E, et al. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res. 1980;17:317-327.
27. Masotti G, Galanti G, Poggesi L, Abbate R, Neri Serneri GG. Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet. 1979;2:1213-1217.
28. Heavey DJ, Barrow SE, Hickling NE, Ritter JM. Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man. Nature. 1985;318:186-188.
29. O’Grady J, Moncada S. Aspirin: a paradoxical effect on bleeding time. Lancet. 1978;2:780.
30. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Ann Rev Public Health. 1987;8:253-287.
31. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990;132:612-628.
32. Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. BMJ. 1974;1:440-443.